GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Millendo Therapeutics Inc (NAS:MLND) » Definitions » Net Intangibles Purchase And Sale

Millendo Therapeutics (Millendo Therapeutics) Net Intangibles Purchase And Sale : $0.00 Mil (TTM As of Mar. 2021)


View and export this data going back to 2012. Start your Free Trial

What is Millendo Therapeutics Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Millendo Therapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2021 was $0.00 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Mar. 2021 was $0.00 Mil.


Millendo Therapeutics Net Intangibles Purchase And Sale Historical Data

The historical data trend for Millendo Therapeutics's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Millendo Therapeutics Net Intangibles Purchase And Sale Chart

Millendo Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Millendo Therapeutics Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Millendo Therapeutics Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Millendo Therapeutics Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of Millendo Therapeutics's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.


Millendo Therapeutics (Millendo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
110 Miller Avenue, Suite 100, Ann Arbor, MI, USA, 48104
Millendo Therapeutics Inc is a biopharmaceutical company.
Executives
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Howe John P Md director C/O BB&T, P O BOX 1250, WINSTON SALEM NC 27102-1250
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Carole Nuechterlein director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Geoffrey Nichol director MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Christophe Arbet-engels officer: Chief Medical Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Ryan Zeidan officer: Chief Development Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Julia C. Owens director, officer: President and CEO C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Tamara L Joseph officer: General Counsel and Secretary 32 GARRISON STREET, APT 50-103, BOSTON MA 02116
Arcudi Iii Louis J officer: Chief Financial Officer C/O IDERA PHARMACEUTICALS 167 SYDNEY ST, CAMBRIDGE MA 02139
Randall W Whitcomb director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Jeffery M. Brinza officer: Sec., CAO and General Counsel C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Pharis Mohideen officer: Chief Medical Officer C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451